From Bench to Bedside: Immunotherapy for Prostate Cancer

被引:16
|
作者
Tse, Brian Wan-Chi [1 ]
Jovanovic, Lidija [1 ]
Nelson, Colleen Coyne [1 ]
de Souza, Paul [2 ]
Power, Carl Andrew [3 ]
Russell, Pamela Joan [1 ]
机构
[1] Queensland Univ Technol, Australian Prostate Canc Res Ctr Queensland, Translat Res Inst, Inst Hlth & Biomed Innovat, Brisbane, Qld 4102, Australia
[2] Univ Western Sydney, Sydney Sch Med, Ingham Inst Appl Med Res, Sydney, NSW 2170, Australia
[3] Univ New S Wales, Lowy Canc Res Ctr, Biol Resources Imaging Lab, Sydney, NSW 2052, Australia
关键词
ALLOGENEIC CELLULAR IMMUNOTHERAPY; REGULATORY T-CELLS; PHASE-I TRIAL; SIPULEUCEL-T; DOSE-ESCALATION; GM-CSF; ADAPTIVE IMMUNITY; CTLA-4; BLOCKADE; DOUBLE-BLIND; OPEN-LABEL;
D O I
10.1155/2014/981434
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The mainstay therapeutic strategy for metastatic castrate-resistant prostate cancer (CRPC) continues to be androgen deprivation therapy usually in combination with chemotherapy or androgen receptor targeting therapy in either sequence, or recently approved novel agents such as Radium 223. However, immunotherapy has also emerged as an option for the treatment of this disease following the approval of sipuleucel-T by the FDA in 2010. Immunotherapy is a rational approach for prostate cancer based on a body of evidence suggesting these cancers are inherently immunogenic and, most importantly, that immunological interventions can induce protective antitumour responses. Various forms of immunotherapy are currently being explored clinically, with the most common being cancer vaccines (dendritic-cell, viral, and whole tumour cell-based) and immune checkpoint inhibition. This review will discuss recent clinical developments of immune-based therapies for prostate cancer that have reached the phase III clinical trial stage. A perspective of how immunotherapy could be best employed within current treatment regimes to achieve most clinical benefits is also provided.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Gene therapy and immunotherapy of advanced prostate cancer: from bench to bedside
    van Ophoven, A
    Patel, B
    Belldegrun, A
    Hinkel, A
    Senge, T
    AKTUELLE UROLOGIE, 1999, 30 (02) : 78 - 88
  • [2] Translation of cancer immunotherapy from the bench to the bedside
    Guo, Qianyu
    Huang, Fan
    Goncalves, Christophe
    del Rincon, Sonia V.
    Miller, Wilson H., Jr.
    IMMUNOTHERAPY OF CANCER, 2019, 143 : 1 - 62
  • [3] Cancer photo-immunotherapy: from bench to bedside
    Wang, Miao
    Rao, Jie
    Wang, Meng
    Li, Xiaosong
    Liu, Kaili
    Naylor, Mark F.
    Nordquist, Robert E.
    Chen, Wei R.
    Zhou, Feifan
    THERANOSTICS, 2021, 11 (05): : 2218 - 2231
  • [4] Prostate cancer - Bench to bedside
    Fowler, JE
    JOURNAL OF UROLOGY, 1996, 156 (05): : 1701 - 1702
  • [5] From bench to bedside a comprehensive review of pancreatic cancer immunotherapy
    Kunk, Paul R.
    Bauer, Todd W.
    Slingluff, Craig L.
    Rahma, Osama E.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2016, 4
  • [6] Local and systhemic immunotherapy for bladder cancer: from bench to bedside
    Carballido, Joaquin A.
    Vazquez Alba, David
    Rodriguez Monsalve, Maria
    ARCHIVOS ESPANOLES DE UROLOGIA, 2020, 73 (10): : 879 - 894
  • [7] Interleukin-10 in cancer immunotherapy: from bench to bedside
    Salkeni, Mohamad Adham
    Naing, Aung
    TRENDS IN CANCER, 2023, 9 (09): : 716 - 725
  • [8] Tertiary lymphoid structures and cancer immunotherapy: From bench to bedside
    Peyraud, Florent
    Guegan, Jean-Philippe
    Vanhersecke, Lucile
    Brunet, Maxime
    Teyssonneau, Diego
    Palmieri, Lola-Jade
    Bessede, Alban
    Italiano, Antoine
    MED, 2025, 6 (01):
  • [9] Predictive immune signatures for cancer immunotherapy - From bench to bedside
    de St Groth, Barbara Fazekas
    McGuire, Helen
    Kao, Steven
    McNeil, Catriona
    Hersey, Peter
    Boyer, Michael
    Vafaee, Fatemeh
    Choi, Clara
    Kwong, Chun-Ting Justin
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 69 - 70
  • [10] Complementary and Alternative Medicines in Prostate Cancer: From Bench to Bedside?
    Klempner, Samuel J.
    Bubley, Glenn
    ONCOLOGIST, 2012, 17 (06): : 830 - 837